Last updated: 2026-09-09 08:35:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Rallybio Corporation (RLYB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $16.92, with a market capitalization of $89.88M and a P/E ratio of 1.94. Over the past 52 weeks, its price has ranged from $3.67 to $17.57. This page covers its latest market performance, valuation, price trends and company information.
$89.88M | |
$16.97 | |
$206.24 | |
$1.76 | |
-- | |
6.75K | |
32.37K | |
1.94 | |
$17.57 | |
$3.67 | |
-- | |
-- |
Rallybio Corporation (RLYB) is trading at $16.88 in pre-market trading as of 2026-09-08 23:58:00, -- from the previous close of $0.00
Pre-market trading shows how investors are pricing RLYB before the regular session opens. The current pre-market price is -- the previous close, indicating positive early trading sentiment.
Over the past seven days, Rallybio Corporation (RLYB) moved from $16.81 to $16.92, representing a gain of 0.67% ($0.11).
The stock traded between $16.39 and $17.26 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 10.66 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 95.3%
RLYB is currently trading at $16.92, placing it 95.3% of the way from its 52-week low of $3.67 to its 52-week high of $17.57. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Rallybio Corporation (RLYB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.